|
Sporadic Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.
|
15355907 |
2004 |
|
Allergy to peanuts
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
An SNP near integrin α6 (ITGA6) reached genome-wide significance with PA (P = 1.80 × 10<sup>-8</sup>), whereas SNPs associated with Src kinase-associated phosphoprotein 1 (SKAP1), matrix metallopeptidase 12 (MMP12)/MMP13, catenin α3 (CTNNA3), rho GTPase-activating protein 24 (ARHGAP24), angiopoietin 4 (ANGPT4), chromosome 11 open reading frame (C11orf30/EMSY), and exocyst complex component 4 (EXOC4) reached a threshold suggestive of association (P ≤ 1.49 × 10<sup>-6</sup>).
|
29030101 |
2018 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
As EMSY is located on 11q13 in proximity to CCND1, an established breast cancer oncogene, we also examined the amplification of CCND1 in the same tumor cohort.
|
21327470 |
2011 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
As EMSY is located on 11q13 in proximity to CCND1, an established breast cancer oncogene, we also examined the amplification of CCND1 in the same tumor cohort.
|
21327470 |
2011 |
|
Prostate cancer, familial
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
PROSTATE CANCER, HEREDITARY, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Prostate carcinoma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Allergic rhinitis (disorder)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Both rs7130588_AG and rs7927894_CT genotypes in EMSY region were associated with a significantly increased risk of AR (1.75-fold and 1.50-fold) compared to the AA and CC genotypes, respectively, specific to moderate-to-severe AR.
|
30170133 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Both CCND1 and EMSY amplifications were associated with a significantly worse outcome in ER-positive patients treated with tamoxifen only, in contrast to nonamplified tumors (P = 8.55 x 10(-4) and P = 8.35 x 10(-5), respectively).
|
19636701 |
2010 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
By reviewing literatures published since 2003, here, we have summarized the recent advances of EMSY in cancer development.
|
24609898 |
2014 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
By reviewing literatures published since 2003, here, we have summarized the recent advances of EMSY in cancer development.
|
24609898 |
2014 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer.
|
18393977 |
2008 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
19636701 |
2010 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
19636701 |
2010 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
19636701 |
2010 |
|
Crohn Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Colon-only CD (n = 228) was compared with healthy controls: three of six UC SNPs (in MST1, HLA-DRA, and IL-23R) and 11 of 34 CD SNPs: in IRGM, NOD2 (rs2066845), CCNY, MST1, IL23R, PTPN22, C11orf30, ZNF365, PTPN2, PSMG1, and rs1456893 were significantly associated.
|
21830272 |
2011 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
Compared to female breast cancers, EGFR (p = 0.005) and CCND1 (p = 0.041) copy number gain was more often seen in male breast cancer, while copy number gain of EMSY (p = 0.004) and CPD (p = 0.001) and amplification in general was less frequent.
|
22527098 |
2012 |
|
Breast Neoplasms, Male
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Considering the relevant role of BRCA2 in MBC, we aimed at investigating the role of EMSY gene copy number variations in male breast tumors.
|
27628328 |
2016 |
|
Prostate carcinoma
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Correlated intronic SNPs rs10899221 and rs72944758 formed with other EMSY variants common and rare haplotypes that were associated with increased risk (P=4.0 × 10(-4)) and decreased risk (P=0.01) of PrCa, respectively.
|
23830236 |
2013 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Correlated intronic SNPs rs10899221 and rs72944758 formed with other EMSY variants common and rare haplotypes that were associated with increased risk (P=4.0 × 10(-4)) and decreased risk (P=0.01) of PrCa, respectively.
|
23830236 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of EMSY gene in sporadic ovarian cancer.
|
20349280 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Expression of EMSY gene in sporadic ovarian cancer.
|
20349280 |
2011 |
|
ovarian neoplasm
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Expression of EMSY gene in sporadic ovarian cancer.
|
20349280 |
2011 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, analysis of a TCGA colorectal cancer dataset revealed that CAB39 and EMSY are upregulated at the protein level in a significant number of CRC patients.
|
29720118 |
2018 |
|
Malignant neoplasm of breast
|
0.380 |
Biomarker
|
disease |
BEFREE |
Genetic alterations of CCND1 and EMSY in breast cancers.
|
18393977 |
2008 |